BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jul 7, 2022
Regulation

July 6 Quick Takes: FDA authorizes pharmacists to prescribe Paxlovid

Plus January PDUFA date for Biogen, Eisai Alzheimer’s therapy, and updates from Genentech, Sarepta, CytomX and more
BioCentury | Mar 12, 2022
Discovery & Translation

Translational highlights to watch for at AACR

BioCentury’s roundup of translational abstracts ahead of the 2022 American Association for Cancer Research conference
BioCentury | Mar 1, 2022
Deals

Feb. 28 Quick Takes: Heidelberg shares jump as Huadong takes stake

Plus FDA approves CTI’s pacritinib, Aurinia shares sink, Lexicon submission delayed, priority review for neoadjuvant Opdivo and more
BioCentury | Jun 23, 2021
Emerging Company Profile

CellPoint: bringing autologous CAR Ts to point of care

Emerging Company Profile: CellPoint aims to broaden access to CAR Ts with point-of-care manufacturing platform
BioCentury | May 26, 2021
Regulation

May 25 Quick Takes: Moderna to submit pediatric COVID vaccine data to regulators in early June; plus FDA guidance on bispecifics, TG, Asylia, Pieris, Nordic, Ziphius and Kyma

Moderna Inc. (NASDAQ:MRNA) will be the next company to bring a COVID-19 vaccine forward for authorization in adolescents, with plans to submit data from the Phase II/III TeenCOVE study of its COVID-19
BioCentury | Mar 1, 2021
Deals

With Phase III started in head and neck cancer, Debiopharm partners lead program with Germany’s Merck

Debiopharm will bank €188 million ($226.6 million) for pipeline development now that the biotech has partnered lead program xevinapant with Merck KGaA, adding the German biopharma’s
BioCentury | Jun 11, 2020
Deals

In course correction, AbbVie steers toward innovation with Genmab deal

AbbVie reaffirms its commitment to cancer, paying $750M up front for rights to a trio of Genmab bispecifics
BioCentury | Jan 18, 2019
Product Development

ImmunoGen’s milestone year

How 2019 could yield first evidence ImmunoGen’s new growth strategy is working
BioCentury | Nov 30, 2018
Targets & Mechanisms

Adhesion targets emerge at ASH 2018

Emerging science on adhesion molecules, RNA-binding proteins and more at ASH 2018
Items per page:
1 - 10 of 68
Username